Drugs / ATAGABALIN
ATAGABALIN
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00722306 | May 2008 | insomnia | Pfizer | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT00748592 | Jan → Jun 2009 | insomnia | Pfizer | Withdrawn | No outcome recorded |
| Phase 2 | NCT00655369 | Apr → Dec 2008 | sleep disorder | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT00551148 | Oct 2007 → Jan 2008 | insomnia | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT00569972 | Oct 2007 → Jan 2009 | insomnia | Pfizer | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ATAGABALIN | ChEMBL registry synonym — accepted as the source's own label CHEMBL593430 ↗ |
| Known as | Atagabalina | ChEMBL registry synonym — accepted as the source's own label CHEMBL593430 ↗ |
| Known as | Atagabaline | ChEMBL registry synonym — accepted as the source's own label CHEMBL593430 ↗ |
| Known as | PD 0200390 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00722306 ↗ |
| Modality | Small molecule | — CHEMBL593430 ↗ |
| Route | Oral | “oral 15 mg dose” NCT00551148 ↗ |